Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Raised to Sell at Wall Street Zen

Maplight Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen raised Maplight Therapeutics’ rating from “strong sell” to “sell.” Broader analyst sentiment remains more positive, with MarketBeat reporting a “Moderate Buy” consensus and an average price target of $29.20.
  • Shares opened at $5.96 after a reported 7.2% decline, close to the stock’s 52-week low of $5.93; its 52-week high is $40.43.
  • The company reported a quarterly loss of $0.97 per share, narrower than analysts’ expected loss of $1.22 per share.
  • Interested in Maplight Therapeutics? Here are five stocks we like better.

Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued on Saturday, Wall Street Zen reports.

MPLT has been the subject of a number of other research reports. Jefferies Financial Group reaffirmed a "buy" rating on shares of Maplight Therapeutics in a research note on Monday, July 27th. Wolfe Research reissued an "outperform" rating and issued a $30.00 price target on shares of Maplight Therapeutics in a research report on Monday, July 27th. Canaccord Genuity Group restated a "buy" rating and issued a $21.00 price target on shares of Maplight Therapeutics in a research note on Tuesday. UBS Group lowered Maplight Therapeutics from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $52.00 to $13.00 in a research report on Monday, August 10th. Finally, Morgan Stanley lowered Maplight Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $34.00 to $21.00 in a research report on Tuesday, July 28th. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Maplight Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $29.20.

Check Out Our Latest Stock Analysis on Maplight Therapeutics

Maplight Therapeutics Trading Down 7.2%

Shares of Maplight Therapeutics stock opened at $5.96 on Friday. The company has a 50-day moving average of $8.63 and a 200 day moving average of $19.56. Maplight Therapeutics has a 1 year low of $5.93 and a 1 year high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.25. Equities research analysts forecast that Maplight Therapeutics will post -4.67 EPS for the current fiscal year.

Insider Buying and Selling at Maplight Therapeutics

In other Maplight Therapeutics news, CFO Jonathan Gillis sold 10,167 shares of the firm's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $8.08, for a total transaction of $82,149.36. Following the completion of the sale, the chief financial officer directly owned 142,315 shares in the company, valued at approximately $1,149,905.20. This trade represents a 6.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Erin Pennock Foff sold 15,355 shares of Maplight Therapeutics stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $8.08, for a total transaction of $124,068.40. Following the completion of the transaction, the insider directly owned 296,906 shares of the company's stock, valued at $2,399,000.48. This trade represents a 4.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 122,974 shares of company stock worth $990,690 in the last 90 days. Insiders own 3.80% of the company's stock.

Hedge Funds Weigh In On Maplight Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Nan Fung Group Holdings Ltd purchased a new stake in shares of Maplight Therapeutics during the second quarter valued at $34,809,708. BlackRock Inc. purchased a new position in Maplight Therapeutics in the 2nd quarter worth about $36,741,000. Blue Owl Capital Holdings LP purchased a new position in Maplight Therapeutics in the 2nd quarter worth about $26,161,000. ADAR1 Capital Management LLC purchased a new position in Maplight Therapeutics in the 1st quarter worth about $7,622,000. Finally, 5AM Venture Management LLC bought a new position in Maplight Therapeutics during the 2nd quarter valued at about $34,048,394.

About Maplight Therapeutics

(Get Free Report)

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for people with serious brain disorders. Its research focuses on treatments intended to address symptoms that can be difficult to manage with existing therapies. The company's investigational programs include ML-007 for schizophrenia and ML-004 for autism spectrum disorder. These candidates remain in development and are not approved medicines.

Featured Articles

Analyst Recommendations for Maplight Therapeutics (NASDAQ:MPLT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Maplight Therapeutics Right Now?

Before you consider Maplight Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maplight Therapeutics wasn't on the list.

While Maplight Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines